



GAVI Alliance

Annual Progress Report 2010

Submitted by
The Government of
Bhutan

Reporting on year: 2010
Requesting for support year: 2012
Date of submission: 29.06.2011 03:11:06

Deadline for submission: 1 Jun 2011

Please submit the APR 2010 using the online platform
<https://AppsPortal.gavialliance.org/PDExtranet>

Enquiries to: apr@gavialliance.org or representatives of a GAVI partner agency. The documents can be shared with GAVI partners, collaborators and general public. The APR and attachments must be submitted in English, French, Spanish, or Russian.

Note: You are encouraged to use previous APRs and approved Proposals for GAVI support as reference documents. The electronic copy of the previous APRs and approved proposals for GAVI support are available at http://www.gavialliance.org/performance/country_results/index.php

The GAVI Secretariat is unable to return submitted documents and attachments to countries. Unless otherwise specified, documents will be shared with the GAVI Alliance partners and the general public.

**GAVI ALLIANCE
GRANT TERMS AND CONDITIONS**

FUNDING USED SOLELY FOR APPROVED PROGRAMMES

The applicant country ("Country") confirms that all funding provided by the GAVI Alliance will be used and applied for the sole purpose of fulfilling the programme(s) described in the Country's application. Any significant change from the approved programme(s) must be reviewed and approved in advance by the GAVI Alliance. All funding decisions for the application are made at the discretion of the GAVI Alliance Board and are subject to IRC processes and the availability of funds.

AMENDMENT TO THE APPLICATION

The Country will notify the GAVI Alliance in its Annual Progress Report if it wishes to propose any change to the programme(s) description in its application. The GAVI Alliance will document any change approved by the GAVI Alliance, and the Country's application will be amended.

RETURN OF FUNDS

The Country agrees to reimburse to the GAVI Alliance all funding amounts that are not used for the programme(s) described in its application. The country's reimbursement must be in US dollars and be provided, unless otherwise decided by the GAVI Alliance, within sixty (60) days after the Country receives the GAVI Alliance's request for a reimbursement and be paid to the account or accounts as directed by the GAVI Alliance.

SUSPENSION/ TERMINATION

The GAVI Alliance may suspend all or part of its funding to the Country if it has reason to suspect that funds have been used for purpose other than for the programmes described in the Country's application, or any GAVI Alliance-approved amendment to the application. The GAVI Alliance retains the right to terminate its support to the Country for the programmes described in its application if a misuse of GAVI Alliance funds is confirmed.

ANTICORRUPTION

The Country confirms that funds provided by the GAVI Alliance shall not be offered by the Country to any third person, nor will the Country seek in connection with its application any gift, payment or benefit directly or indirectly that could be construed as an illegal or corrupt practice.

AUDITS AND RECORDS

The Country will conduct annual financial audits, and share these with the GAVI Alliance, as requested. The GAVI Alliance reserves the right, on its own or through an agent, to perform audits or other financial management assessment to ensure the accountability of funds disbursed to the Country.

The Country will maintain accurate accounting records documenting how GAVI Alliance funds are used. The Country will maintain its accounting records in accordance with its government-approved accounting standards for at least three years after the date of last disbursement of GAVI Alliance funds. If there is any claims of misuse of funds, Country will maintain such records until the audit findings are final. The Country agrees not to assert any documentary privilege against the GAVI Alliance in connection with any audit.

CONFIRMATION OF LEGAL VALIDITY

The Country and the signatories for the Country confirm that its application, and Annual Progress Report, are accurate and correct and form legally binding obligations on the Country, under the Country's law, to perform the programmes described in its application, as amended, if applicable, in the APR.

CONFIRMATION OF COMPLIANCE WITH THE GAVI ALLIANCE TRANSPARENCY AND ACCOUNTABILITY POLICY

The Country confirms that it is familiar with the GAVI Alliance Transparency and Accountability Policy (TAP) and complies with the requirements therein.

USE OF COMMERCIAL BANK ACCOUNTS

The Country is responsible for undertaking the necessary due diligence on all commercial banks used to manage GAVI cash-based support. The Country confirms that it will take all responsibility for replenishing GAVI cash support lost due to bank insolvency, fraud or any other unforeseen event.

ARBITRATION

Any dispute between the Country and the GAVI Alliance arising out of or relating to its application that is not settled amicably within a reasonable period of time, will be submitted to arbitration at the request of either the GAVI Alliance or the Country. The arbitration will be conducted in accordance with the then-current UNCITRAL Arbitration Rules. The parties agree to be bound by the arbitration award, as the final adjudication of any such dispute. The place of arbitration will be Geneva, Switzerland. The language of the arbitration will be English.

For any dispute for which the amount at issue is US\$ 100,000 or less, there will be one arbitrator appointed by the GAVI Alliance. For any dispute for which the amount at issue is greater than US \$100,000 there will be three arbitrators appointed as follows: The GAVI Alliance and the Country will each appoint one arbitrator, and the two arbitrators so appointed will jointly appoint a third arbitrator who shall be the chairperson.

The GAVI Alliance will not be liable to the country for any claim or loss relating to the programmes described in the application, including without limitation, any financial loss, reliance claims, any harm to property, or personal injury or death. Country is solely responsible for all aspects of managing and implementing the programmes described in its application.

By filling this APR the country will inform GAVI about:

- Accomplishments using GAVI resources in the past year
- Important problems that were encountered and how the country has tried to overcome them
- Meeting accountability needs concerning the use of GAVI disbursed funding and in-country arrangements with development partners
- Requesting more funds that had been approved in previous application for ISS/NVS/HSS, but have not yet been released
- How GAVI can make the APR more user-friendly while meeting GAVI's principles to be accountable and transparent.

1. Application Specification

Reporting on year: 2010

Requesting for support year: 2012

1.1. NVS & INS support

Type of Support	Current Vaccine	Preferred presentation	Active until
NVS	DTP-HepB, 2 doses/vial, Liquid	DTP-HepB, 2 doses/vial, Liquid	2011
NVS	DTP-HepB-Hib, 1 dose/vial, Liquid	DTP-HepB-Hib, 1 dose/vial, Liquid	2013

Programme extension

Note: To add new lines click on the *New item* icon in the *Action* column.

Type of Support	Vaccine	Start Year	End Year	Action
	Change Vaccine			

1.2. ISS, HSS, CSO support

Type of Support	Active until
HSS	2012

2. Signatures

Please fill in all the fields highlighted in blue. Afterwards, please print this page, have relevant people dated and signed, then upload the scanned signature documents in Section 13 "Attachments".

2.1. Government Signatures Page for all GAVI Support (ISS, INS, NVS, HSS, CSO)

By signing this page, the Government of Bhutan hereby attests the validity of the information provided in the report, including all attachments, annexes, financial statements and/or audit reports. The Government further confirms that vaccines, supplies, and funding were used in accordance with the GAVI Alliance Standard Grant Terms and Conditions as stated in this Annual Progress Report (APR).

For the Government of Bhutan

Please note that this APR will not be reviewed or approved by the Independent Review Committee (IRC) without the signatures of both the Minister of Health & Minister Finance or their delegated authority.

Enter the family name in capital letters.

Minister of Health (or delegated authority):		Minister of Finance (or delegated authority)	
Name	Dr.Gado Tshering, Secretary, Ministry of Health	Name	Mr.Karma Tshetrim, Secretary, Gross National Happiness Commission
Date		Date	
Signature		Signature	

This report has been compiled by

Note: To add new lines click on the **New item** icon in the **Action** column.
Enter the family name in capital letters.

Full name	Position	Telephone	Email	Action
Tshewang Dorji Tamang	Program Officer	+975-1787-6745	t_tamang@health.gov.bt	
Sangay Phuntsho	Assistant Program Officer	+975-1768-9190	sunnypinso@health.gov.bt	
Tshering Wangdi	Assistant Planning Officer	+975-1787-7763	t_wangdi@health.gov.bt	

2.2. ICC Signatures Page

If the country is reporting on Immunisation Services (ISS), Injection Safety (INS), and/or New and Under-Used Vaccines (NVS) supports

The GAVI Alliance Transparency and Accountability Policy (TAP) is an integral part of GAVI Alliance monitoring of country performance. By signing this form the ICC members confirm that the funds received from the GAVI Alliance have been used for purposes stated within the approved application and managed in a transparent manner, in accordance with government rules and regulations for financial management.

2.2.1. ICC report endorsement

We, the undersigned members of the immunisation Inter-Agency Coordinating Committee (ICC), endorse this report. Signature of endorsement of this document does not imply any financial (or legal) commitment on the part of the partner agency or individual.

Note: To add new lines click on the **New item** icon in the **Action** column.
Enter the family name in capital letters.

Name/Title	Agency/Organisation	Signature	Date	Action

ICC may wish to send informal comments to: apr@gavialliance.org

All comments will be treated confidentially

Comments from Partners:

Comments from the Regional Working Group:

2.3. HSCC Signatures Page

If the country is reporting on HSS

The GAVI Alliance Transparency and Accountability Policy is an integral part of GAVI Alliance monitoring of country performance. By signing this form the HSCC members confirm that the funds received from the GAVI Alliance have been used for purposes stated within the approved application and managed in a transparent manner, in accordance with government rules and regulations for financial management. Furthermore, the HSCC confirms that the content of this report has been based upon accurate and verifiable financial reporting.

2.3.1. HSS report endorsement

We, the undersigned members of the National Health Sector Coordinating Committee (HSCC) - Partner Coordination Mechanism (PCM), endorse this report on the Health Systems Strengthening Programme. Signature of endorsement of this document does not imply any financial (or legal) commitment on the part of the partner agency or individual.

Note: To add new lines click on the **New item** icon in the **Action** column.

Action.

Enter the family name in capital letters.

Name/Title	Agency/Organisation	Signature	Date	Action
Ms. Phuntshok Chhoden, Vice Chairman	Secretary General, Bhutan Association of Women Entrepreneurs			
Mr. Kesang Wangdi, Dy. Secretary	Bhutan Chamber of Commerce and Industry			
Mr. Rinchen Wangdi, Chief Program Coordinator	Gross National Happiness Commission			
Mr. Bikash Thapa, Chief Budget Officer	DNB, Ministry of Finance			
Dr. Nani Nair, WR	World Health Organization, Country Office			
Mr. Kinley Tenzin, Program Officer	Youth Development Fund			
Ms. Chhimi Wangmo, Director	RENEW			
Ms. Dechen Zam, Chief Planning Officer	Ministry of Education			
Dr. Ugen Dophu, Director	Department of Public Health, MoH			

HSCC may wish to send informal comments to: apr@gavialliance.org

All comments will be treated confidentially

Comments from Partners:

Comments from the Regional Working Group:

--

2.4. Signatures Page for GAVI Alliance CSO Support (Type A & B)

This report has been prepared in consultation with CSO representatives participating in national level coordination mechanisms (HSCC or equivalent and ICC) and those involved in the mapping exercise (for Type A funding), and those receiving support from the GAVI Alliance to help implement the GAVI HSS proposal or cMYP (for Type B funding).

2.4.1. CSO report editors

This report on the GAVI Alliance CSO Support has been completed by

Note: To add new lines click on the **New item** icon in the **Action** column.
Enter the family name in capital letters.

Name/Title	Agency/Organisation	Signature	Date	Action

2.4.2. CSO report endorsement

We, the undersigned members of the National Health Sector Coordinating Committee - **Partner Coordination Mechanism (PCM)**, endorse this report on the GAVI Alliance CSO Support.

Note: To add new lines click on the **New item** icon in the **Action** column.
Enter the family name in capital letters.

Name/Title	Agency/Organisation	Signature	Date	Action

Signature of endorsement does not imply any financial (or legal) commitment on the part of the partner agency or individual.

3. Table of Contents

This APR reports on Bhutan's activities between January - December 2010 and specifies the requests for the period of January - December 2012

Sections

Main

Cover Page
GAVI Alliance Grant Terms and Conditions

1. Application Specification

- 1.1. NVS & INS
- 1.2. Other types of support

2. Signatures

- 2.1. Government Signatures Page for all GAVI Support (ISS, INS, NVS, HSS, CSO)
- 2.2. ICC Signatures Page
- 2.3. HSCC Signatures Page
- 2.4. Signatures Page for GAVI Alliance CSO Support (Type A & B)

3. Table of Contents

4. Baseline and Annual Targets

Table 1: Baseline figures

5. General Programme Management Component

- 5.1. Updated baseline and annual targets
- 5.2. Immunisation achievements in 2010
- 5.3. Data assessments
- 5.4. Overall Expenditures and Financing for Immunisation
 - Table 2a:** Overall Expenditure and Financing for Immunisation
 - Table 2b:** Overall Budgeted Expenditures for Immunisation
- 5.5. Inter-Agency Coordinating Committee (ICC)
- 5.6. Priority actions in 2011 to 2012
- 5.7. Progress of transition plan for injection safety

6. Immunisation Services Support (ISS)

7. New and Under-Used Vaccines Support (NVS)

- 7.1. Receipt of new & under-used vaccines for 2010 vaccination programme
 - Table 4:** Received vaccine doses
- 7.2. Introduction of a New Vaccine in 2010
- 7.3. Report on country co-financing in 2010 (if applicable)
 - Table 5:** Four questions on country co-financing in 2010
- 7.4. Vaccine Management (EVSM/VMA/EVM)
- 7.5. Change of vaccine presentation
- 7.6. Renewal of multi-year vaccines support for those countries whose current support is ending in 2011
- 7.7. Request for continued support for vaccines for 2012 vaccination programme
- 7.8. UNICEF Supply Division: weighted average prices of supply and related freight cost
 - Table 6.1:** UNICEF prices

Table 6.2: Freight costs
7.9. Calculation of requirements

Table 7.1.1: Specifications for DTP-HepB-Hib, 1 dose/vial, Liquid
Co-financing tables for DTP-HepB-Hib, 1 dose/vial, Liquid

Table 7.1.2: Estimated GAVI support and country co-financing (GAVI support)

Table 7.1.3: Estimated GAVI support and country co-financing (Country support)

Table 7.1.4: Calculation of requirements

8. Injection Safety Support (INS)

9. Health System Strengthening Programme (HSS)

10. Civil Society Programme (CSO)

11. Comments

12. Annexes

Financial statements for immunisation services support (ISS) and new vaccine introduction grants

Financial statements for health systems strengthening (HSS)

Financial statements for civil society organisation (CSO) type B

13. Attachments

13.1. List of Supporting Documents Attached to this APR

13.2. Attachments

4. Baseline and Annual Targets

Table 1: baseline figures

Number	Achievements as per JRF	Targets				
	2010	2011	2012	2013		
Total births	13,825	14,165	14,413	14,660		
Total infants' deaths						
Total surviving infants	13,825	14,165	14,413	14,660		
Total pregnant women	13,825	14,165	14,413	14,660		
# of infants vaccinated (to be vaccinated) with BCG	13,258	13,598	13,981	14,220		
BCG coverage (%) *	96%	96%	97%	97%		
# of infants vaccinated (to be vaccinated) with OPV3	12,766	13,456	13,692	14,220		
OPV3 coverage (%) **	92%	95%	95%	97%		
# of infants vaccinated (or to be vaccinated) with DTP1 ***	12,935	13,456	13,692	14,073		
# of infants vaccinated (to be vaccinated) with DTP3 ***	12,625	13,315	13,548	13,927		
DTP3 coverage (%) **	91%	94%	94%	95%		
Wastage ^[1] rate in base-year and planned thereafter (%)	40%	40%	40%	35%		
Wastage ^[1] factor in base-year and planned thereafter	1.67	1.67	1.67	1.54		
Infants vaccinated (to be vaccinated) with 1 st dose of HepB and/or Hib	12,935	13,456	13,692	14,073		
Infants vaccinated (to be vaccinated) with 3 rd dose of HepB and/or Hib	12,625	13,315	13,548	13,927		
3 rd dose coverage (%) **	91%	94%	94%	95%		
Wastage ^[1] rate in base-year and planned thereafter (%)	45%	40%	40%	35%		
Wastage ^[1] factor in base-year and planned thereafter	1.82	1.67	1.67	1.54		

Number	Achievements as per JRF	Targets				
	2010	2011	2012	2013		
Infants vaccinated (to be vaccinated) with 1 st dose of Measles	13,090	13,598	13,980	14,220		
Measles coverage (%) **	95%	96%	97%	97%		
Pregnant women vaccinated with TT+	11,287	11,615	11,962	12,167		
TT+ coverage (%) ****	82%	82%	83%	83%		
Vit A supplement to mothers within 6 weeks from delivery	12,220					
Vit A supplement to infants after 6 months	15,676					
Annual DTP Drop-out rate [(DTP1 - DTP3) / DTP1] x 100	2%	1%	1%	1%		

* Number of infants vaccinated out of total births

** Number of infants vaccinated out of total surviving infants

*** Indicate total number of children vaccinated with either DTP alone or combined

**** Number of pregnant women vaccinated with TT+ out of total pregnant women

¹ The formula to calculate a vaccine wastage rate (in percentage): $[(A - B) / A] \times 100$. Whereby: A = the number of doses distributed for use according to the supply records with correction for stock balance at the end of the supply period; B = the number of vaccinations with the same vaccine in the same period.

5. General Programme Management Component

5.1. Updated baseline and annual targets

Note: Fill-in the table in section 4 [Baseline and Annual Targets](#) before you continue.

The numbers for **2010** must be consistent with those that the country reported in the **WHO/UNICEF Joint Reporting Form (JRF) for 2010**. The numbers for **2011** to **2015** in the table on section 4 [Baseline and Annual Targets](#) should be consistent with those that the country provided to GAVI in the previous APR or in the new application for GAVI support or in cMYP.

In the fields below, please provide justification and reasons for those numbers that in this APR are different from the referenced ones

Provide justification for any changes in **births**

Provide justification for any changes in **surviving infants**

Provide justification for any changes in **targets by vaccine**

There is slightly changes in the target population in 2010, which was submitted as per APR 2009. It was due to slight error in the calculation of denominator. We have planed to discuss with the National Statistical Bereau (NSB) as soon as possible to make necessary correction.

Provide justification for any changes in **wastage by vaccine**

Vaccine		wastage	in		2010
BCG	=	88	DTP-Hep.B	=	43
OPV	=52 and Measles	64			

5.2. Immunisation achievements in **2010**

5.2.1.

Please comment on the achievements of immunisation programme against targets (as stated in last year APR), the key major activities conducted and the challenges faced in **2010** and how these were addressed

Following were the acheivements made in 2010:

1.	Formulated	national	Immuinization	Policy
2.	Revised	EPI	manual	
3.	Revised	AFP	guidelines	
4.	Trained one medical specialist and one drug controller on vaccinology course in South Korea. Both were NCIP members			
5.	Health workers	trained on	reveised	EPI manual
6.	Three EPI techncians	were trained on	vaccine management	in India]
7.	Nationwide HPV vaccination	campaign was conducted	for girls	12-18years
8.	National Committee for Immunization Practice (NCIP) members trained on AEFI Advance Causality Assessment by WHO experts			
9.	Acute Flaccid Paralysis (AFP) Surveillance Officers were trained on surveillance system by WHO experts			
10.	H1N1 Vaccination was given to higher risk groups (Pregnant mothers, Childern below 2yrs, health workers and Chronic Disease Patients)			
11.	Developed communication	action plan	for pentavalent vaccine	re-introduction
12.	Supervision and	monitoring	was conducted	with JICA expert
13.	Developed	HPV and	H1N1 health	workers manuals

5.2.2.

If targets were not reached, please comment on the reasons for not reaching the targets

Imunization coverage was slightly dropped due to vaccine stock out and error in calculating the denominator

5.2.3.

Do males and females have equal access to the immunisation services? **Yes**

If No, please describe how you plan to improve the equal access of males and females to the immunisation services.

If no data available, do you plan in the future to collect sex-disaggregated data on routine immunisation reporting? **No**

If Yes, please give a brief description on how you have achieved the equal access.

The immunization services in the country does not discriminate gender. The immunization services are provided to all children irrespective of their gender. However, there is no separate gender wise reporting system in the country but at the health facilities level, the immunization records are maintained in gender wise.

5.2.4.

Please comment on the achievements and challenges in **2010** on ensuring males and females having equal access to the immunisation services

All children have equal access to immunization services

5.3. Data assessments

5.3.1.

Please comment on any discrepancies between immunisation coverage data from different sources (for example, if survey data indicate coverage levels that are different than those measured through the administrative data system, or if the WHO/UNICEF Estimate of National Immunisation Coverage and the official country estimate are different)*.

As per the EPI coverage survey, 2008 and administrative data system, there is no much discrepancies in the reported coverage

* Please note that the WHO UNICEF estimates for **2010** will only be available in **July 2011** and can have retrospective changes on the time series.

5.3.2.

Have any assessments of administrative data systems been conducted from **2009** to the present? **No**

If Yes, please describe the assessment(s) and when they took place.

5.3.3.

Please describe any activities undertaken to improve administrative data systems from 2008 to the present.

All the districts and health facilities have been instructed to segregate the recording of immunization data within their catchment area and clients from other catchment areas

5.3.4.

Please describe any plans that are in place, or will be put into place, to make further improvements to administrative data systems.

Data quality assessment is planed in 2012 to enhance the administrative data system

5.4. Overall Expenditures and Financing for Immunisation

The purpose of **Table 2a** and **Table 2b** below is to guide GAVI understanding of the broad trends in immunisation programme expenditures and financial flows. Please fill-in the table using US\$.

Exchange rate used	1 \$US = 45	Enter the rate only; no local currency name
---------------------------	-------------	---

Table 2a: Overall Expenditure and Financing for Immunisation from all sources (Government and donors) in US\$

Note: To add new lines click on the *New item* icon in the *Action* column.

Expenditures by Category	Expenditures Year 2010	Sources of Funding							Actions
		Country	GAVI	UNICEF	WHO	Donor name	Donor name	Donor name	
Traditional Vaccines*	52,968								
New Vaccines	264,000								
Injection supplies with AD syringes	23,400								
Injection supply with syringes other than ADs	0								
Cold Chain equipment	100,000								
Personnel									
Other operational costs	90,000								
Supplemental Immunisation Activities									
HPV Vaccination Campaign	308,000								
Total Expenditures for Immunisation	838,368								
Total Government Health									

* Traditional vaccines: BCG, DTP, OPV (or IPV), Measles 1st dose (or the combined MR, MMR), TT. Some countries will also include HepB and Hib vaccines in this row, if these vaccines were introduced without GAVI support.

Table 2b: Overall Budgeted Expenditures for Immunisation from all sources (Government and donors) in US\$.

Note: To add new lines click on the **New item** icon in the **Action** column

<i>Expenditures by Category</i>	Budgeted Year 2012	Budgeted Year 2013	Action s
Traditional Vaccines*	106,420	117,062	
New Vaccines	0	0	
Injection supplies with AD syringes	25,000	30,000	
Injection supply with syringes other than ADs	0	0	
Cold Chain equipment	100,000	150,000	
Personnel			
Other operational costs			
Supplemental Immunisation Activities	0	0	
Total Expenditures for Immunisation	231,420	297,062	

* Traditional vaccines: BCG, DTP, OPV (or IPV), Measles 1st dose (or the combined MR, MMR), TT. Some countries will also include HepB and Hib vaccines in this row, if these vaccines were introduced without GAVI support.

Please describe trends in immunisation expenditures and financing for the reporting year, such as differences between planned versus actual expenditures, financing and gaps. Give details on the reasons for the reported trends and describe the financial sustainability prospects for the immunisation program over the next three years; whether the funding gaps are manageable, challenging, or alarming. If either of the latter two is applicable, please explain the strategies being pursued to address the gaps and indicate the sources/causes of the gaps.

When Bhutan graduates from receiving the donor's support for vaccine, the expenditure for procurement of vaccine will be borne by Bhutan Health Trust Fund (BHTF) and other operational cost will be met from the regular WHO/UNICEF/Royal Government of Bhutan (RGoB) support for the Program.

5.5. Inter-Agency Coordinating Committee (ICC)

How many times did the ICC meet in 2010? 1

Please attach the minutes (Document number 1) from all the ICC meetings held in 2010, including those of the meeting endorsing this report.

List the key concerns or recommendations, if any, made by the ICC on sections [5.1 Updated baseline and annual targets](#) to [5.4 Overall Expenditures and Financing for Immunisation](#)

The ICC members are same with the Country Coordinating Mechanism (CCM) members. During the meeting, the members have briefed on the status of activities under GAVI support.

Are there any Civil Society Organisations (CSO) member of the ICC?: Yes

If Yes, which ones?

Note: To add new lines click on the **New item** icon in the **Action** column.

List CSO member organisations:	Actions
Youth Development Fund (YDF) and BAWE	

List CSO member organisations:	Actions
Tarayana Foundation and RENEW	

5.6. Priority actions in 2011 to 2012

What are the country's main objectives and priority actions for its EPI programme for 2011 to 2012? Are they linked with cMYP?

The following activities were prioritized for 2011 and 2012:

1. To re-introduce pentavalent vaccine in June, 2011
2. To maintain immunization coverage above 95%
3. Mid Level management training for District Health Officers and medical officer in charges

5.7. Progress of transition plan for injection safety

For all countries, please report on progress of transition plan for injection safety.

Please report what types of syringes are used and the funding sources of Injection Safety material in 2010

Note: To add new lines click on the **New item** icon in the **Action** column.

Vaccine	Types of syringe used in 2010 routine EPI	Funding sources of 2010	Actions
BCG	AD Syringes	JCV	
Measles	AD Syringes	JCV	
TT	AD Syringes	JCV	
DTP-containing vaccine			

Does the country have an injection safety policy/plan? Yes

If Yes: Have you encountered any obstacles during the implementation of this injection safety policy/plan? (Please report in box below)

If No: When will the country develop the injection safety policy/plan? (Please report in box below)

There is no separate injection safety policy plans but it has been incorporated with the EPI manual. There is no obstacles during the implementation of this policy as being integrated with the EPI Manual

Please explain in 2010 how sharps waste is being disposed of, problems encountered, etc.

The sharps waste were collected in the safety boxes and buried and burnt as per the infection control guideline and EPI manual

6. Immunisation Services Support (ISS)

There is no ISS support this year.

7. New and Under-used Vaccines Support (NVS)

7.1. Receipt of new & under-used vaccines for 2010 vaccination programme

7.1.1.

Did you receive the approved amount of vaccine doses for 2010 Immunisation Programme that GAVI communicated to you in its Decision Letter (DL)? Fill-in **Table 4** below.

Table 4: Received vaccine doses

Note: To add new lines click on the **New item** icon in the **Action** column.

	[A]	[B]		
Vaccine Type	Total doses for 2010 in DL	Total doses received by 31 December 2010 *	Total doses of postponed deliveries in 2011	Actions
DTP-HepB	26,400	26,400	0	
DTP-HepB-Hib	0	0	0	

* Please also include any deliveries from the previous year received against this DL

If numbers [A] and [B] above are different

What are the main problems encountered? (Lower vaccine utilisation than anticipated? Delay in shipments? Stock-outs? Excessive stocks? Problems with cold chain? Doses discarded because VVM changed colour or because of the expiry date? ...)

What actions have you taken to improve the vaccine management, e.g. such as adjusting the plan for vaccine shipments? (in the country and with UNICEF Supply Division)

7.1.2.

For the vaccines in the **Table 4** above, has your country faced stock-out situation in 2010? **Yes**

If **Yes**, how long did the stock-out last? **2 weeks (apprx)**

Please describe the reason and impact of stock-out

The reason for stock out was due to delay in receiving the DTP-Hep B vaccine when we switched from the original request for penta to an urgent request to switch to DTP-Hep B

7.2. Introduction of a New Vaccine in 2010

7.2.1.

If you have been approved by GAVI to introduce a new vaccine in 2010, please refer to the vaccine introduction plan in the proposal approved and report on achievements

Vaccine introduced	0
--------------------	---

Phased introduction		Date of introduction
Nationwide introduction		Date of introduction
The time and scale of introduction was as planned in the proposal?		If No, why?

7.2.2.

When is the Post introduction Evaluation (PIE) planned? **NA**

If your country conducted a PIE in the past two years, please attach relevant reports (Document No **NA**)

7.2.3.

Has any case of Adverse Event Following Immunisation (AEFI) been reported in **2010** calendar year? **Yes**

If AEFI cases were reported in **2010**, please describe how the AEFI cases were dealt with and their impact on vaccine introduction

Two serious AEFIs were reported in 2010 and the cases were investigated by the national AEFI Technical Committee and discarded as unrelated with the vaccine. Since there was no new vaccine introduction, there was no impact on vaccine introduction.

7.2.4.

Use of new vaccines introduction grant (or lump-sum)

Funds of Vaccines Introduction Grant received in **2010**

\$US	0
Receipt date	

Please report on major activities that have been undertaken in relation to the introduction of a new vaccine, using the GAVI New Vaccine Introduction Grant

There was no new vaccine introduction in 2010

Please describe any problem encountered in the implementation of the planned activities

Pentavalent vaccine was introduced in 1st September, 2009 and has been suspended on 23rd October, 2009 due to suspected AEFI cases being reported after the vaccination. Immediately after suspension, detail joint national and international investigations were carried out:

1. Random vaccine samples were sent for laboratory safety test in WHO accredited laboratories in Paris, France and Bangkok, Thailand found that vaccine was safe and non-toxic
2. Laboratory tests on CSF in CDC, USA found no causative microorganisms
3. Case sheet analysis sent in South Australia and Canada. The case history was reviewed by WHO experts and classified that the cases were unlikely- that the vaccines caused the meningo-encephalitis in the reported cases
4. Same batch of pentavalent vaccine used in Bhutan were also used in Gambia and Sao Tome but no AEFIs reported

Therefore, pentavalent vaccine will be re-introduced in June, 2011.

The details of the pentavalent vaccine used in Bhutan:

Manufactured by: Panacea Biotec Ltd, New Delhi, India

Vaccine batch No. : P9010/SBP

Expiry date : January, 2011

Presentation : 0.5ml (Single dose)

No. of doses received : 30300

No. of doses dispensed : 4069

No. of doses discarded : 26231

The remaining 26231 doses after the suspension was discarded as per the Government policy due to expiry of the vaccines

Is there a balance of the introduction grant that will be carried forward? **No**

If Yes, how much? US\$ **0**

Please describe the activities that will be undertaken with the balance of funds

NA

7.2.5.

Detailed expenditure of New Vaccines Introduction Grant funds during the 2010 calendar year

Please attach a detailed financial statement for the use of New Vaccines Introduction Grant funds in the 2010 calendar year (Document No). (Terms of reference for this financial statement are available in [Annex 1](#).) Financial statements should be signed by the Chief Accountant or by the Permanent Secretary of Ministry of Health.

7.3. Report on country co-financing in 2010 (if applicable)

Table 5: Four questions on country co-financing in 2010

Q. 1: What are the actual co-financed amounts and doses in 2010?		
Co-Financed Payments	Total Amount in US\$	Total Amount in Doses
1st Awarded Vaccine DTP-HepB, 2 doses/vial, Liquid	5,500	68,000
2nd Awarded Vaccine DTP-HepB-Hib, 1 dose/vial, Liquid		
3rd Awarded Vaccine		
Q. 2: Which are the sources of funding for co-financing?		
Government		
Donor		
Other	Bhutan Health Trust Fund	
Q. 3: What factors have accelerated, slowed, or hindered mobilisation of resources for vaccine co-financing?		

1.	
2.	
3.	
4.	
Q. 4: How have the proposed payment schedules and actual schedules differed in the reporting year?	
Schedule of Co-Financing Payments	Proposed Payment Date for 2012
	(month number e.g. 8 for August)
1 st Awarded Vaccine DTP-HepB, 2 doses/vial, Liquid	
2 nd Awarded Vaccine DTP-HepB-Hib, 1 dose/vial, Liquid	
3 rd Awarded Vaccine	

If the country is in default please describe and explain the steps the country is planning to take to meet its co-financing requirements. For more information, please see the GAVI Alliance Default Policy: http://www.gavialliance.org/resources/9_Co_Financing_Default_Policy.pdf.

Is GAVI's new vaccine support reported on the national health sector budget? **No**

7.4. Vaccine Management (EVSM/VMA/EVM)

Under new guidelines, it will be mandatory for the countries to conduct an EVM prior to an application for introduction of new vaccine.

When was the last Effective Vaccine Store Management (EVSM) conducted?

When was the last Vaccine Management Assessment (VMA) conducted?

If your country conducted either EVSM or VMA in the past three years, please attach relevant reports. (Document N° **No**)

A VMA report must be attached from those countries which have introduced a New and Underused Vaccine with GAVI support before 2008.

Please note that EVSM and VMA tools have been replaced by an integrated Effective Vaccine Management (EVM) tool. The information on EVM tool can be found at http://www.who.int/immunisation_delivery/systems_policy/logistics/en/index6.html.

For countries which conducted EVSM, VMA or EVM in the past, please report on activities carried out as part of either action plan or improvement plan prepared after the EVSM/VMA/EVM.

There was no EVSM and VMA conducted in the past. However, it is planned in 2012

When is the next Effective Vaccine Management (EVM) Assessment planned? **10.04.2012**

7.5. Change of vaccine presentation

If you would prefer, during **2012**, to receive a vaccine presentation which differs from what you are currently being supplied (for instance the number of doses per vial, from one form

(liquid/lyophilised) to the other, ...), please provide the vaccine specifications and refer to the minutes of the ICC meeting recommending the change of vaccine presentation. If supplied through UNICEF, planning for a switch in presentation should be initiated following the issuance of Decision Letter (DL) for next year, taking into account country activities needed in order to switch as well as supply availability.

Please specify below the new vaccine presentation

We will be using Pentavalent single dose vial which is being supplied through UNICEF. There is no plans to switch in the vaccine presentation.

Please attach the minutes of the ICC and NITAG (if available) meeting (Document No) that has endorsed the requested change.

7.6. Renewal of multi-year vaccines support for those countries whose current support is ending in 2011

If 2011 is the last year of approved multiyear support for a certain vaccine and the country wishes to extend GAVI support, the country should request for an extension of the co-financing agreement with GAVI for vaccine support starting from 2012 and for the duration of a new Comprehensive Multi-Year Plan (cMYP).

The country hereby request for an extension of GAVI support for vaccine for the years 2012 to . At the same time it commits itself to co-finance the procurement of vaccine in accordance with the minimum GAVI co-financing levels as summarised in section [7.9 Calculation of requirements](#).

The multi-year extension of vaccine support is in line with the new cMYP for the years 2012 to which is attached to this APR (Document No).

The country ICC has endorsed this request for extended support of vaccine at the ICC meeting whose minutes are attached to this APR (Document No).

7.7. Request for continued support for vaccines for 2012 vaccination programme

In order to request NVS support for 2012 vaccination do the following

Confirm here below that your request for 2012 vaccines support is as per section [7.9 Calculation of requirements](#): Yes

If you don't confirm, please explain

7.8. Weighted average prices of supply and related freight cost

Table 6.1: Commodities Cost

Estimated prices of supply and related freight cost: 2011 from UNICEF Supply Division; 2012 onwards: GAVI Secretariat

Vaccine	Presentation	2011	2012	2013	2014	2015
AD-SYRINGE	0	0.053	0.053	0.053	0.053	0.053
DTP-HepB, 2 doses/vial, Liquid	2	1.600				
DTP-HepB, 10 doses/vial, Liquid	10	0.620	0.620	0.620	0.620	0.620
DTP-HepB-Hib, 1 dose/vial, Liquid	WAP	2.580	2.470	2.320	2.030	1.850
DTP-HepB-Hib, 2 doses/vial, Lyophilised	WAP	2.580	2.470	2.320	2.030	1.850
DTP-HepB-Hib, 10 doses/vial, Liquid	WAP	2.580	2.470	2.320	2.030	1.850
DTP-Hib, 10 doses/vial, Liquid	10	3.400	3.400	3.400	3.400	3.400
HepB monoval, 1 dose/vial, Liquid	1					
HepB monoval, 2 doses/vial, Liquid	2					
Hib monoval, 1 dose/vial, Lyophilised	1	3.400				
Measles, 10 doses/vial, Lyophilised	10	0.240	0.240	0.240	0.240	0.240
Pneumococcal (PCV10), 2 doses/vial, Liquid	2	3.500	3.500	3.500	3.500	3.500
Pneumococcal (PCV13), 1 doses/vial, Liquid	1	3.500	3.500	3.500	3.500	3.500
RECONSTIT-SYRINGE-PENTAVAL	0	0.032	0.032	0.032	0.032	0.032
RECONSTIT-SYRINGE-YF	0	0.038	0.038	0.038	0.038	0.038
Rotavirus 2-dose schedule	1	7.500	6.000	5.000	4.000	3.600
Rotavirus 3-dose schedule	1	5.500	4.000	3.333	2.667	2.400
SAFETY-BOX	0	0.640	0.640	0.640	0.640	0.640
Yellow Fever, 5 doses/vial, Lyophilised	WAP	0.856	0.856	0.856	0.856	0.856
Yellow Fever, 10 doses/vial, Lyophilised	WAP	0.856	0.856	0.856	0.856	0.856

Note: WAP - weighted average price (to be used for any presentation: For DTP-HepB-Hib, it applies to 1 dose liquid, 2 dose lyophilised and 10 dose liquid. For Yellow Fever, it applies to 5 dose lyophilised and 10 dose lyophilised)

Table 6.2: Freight Cost

Vaccines	Group	No Threshold	200'000 \$		250'000 \$		2'000'000 \$	
			<=	>	<=	>	<=	>
Yellow Fever	Yellow Fever		20%				10%	5%
DTP+HepB	HepB and or Hib	2%						
DTP-HepB-Hib	HepB and or Hib				15%	3,50%		
Pneumococcal vaccine (PCV10)	Pneumococcal	5%						
Pneumococcal vaccine (PCV13)	Pneumococcal	5%						
Rotavirus	Rotavirus	5%						
Measles	Measles	10%						

7.9. Calculation of requirements

Table 7.1.1: Specifications for DTP-HepB-Hib, 1 dose/vial, Liquid

	Instructions		2011	2012	2013				TOTAL
Number of Surviving infants	Table 1	#	14,165	14,413	14,660				43,238
Number of children to be vaccinated with the third dose	Table 1	#	13,315	13,548	13,927				40,790
Immunisation coverage with the third dose	Table 1	#	94%	94%	95%				
Number of children to be vaccinated with the first dose	Table 1	#	13,456	13,692	14,073				41,221
Number of doses per child		#	3	3	3				
Estimated vaccine wastage factor	Table 1	#	1.67	1.67	1.54				

	Instructions		2011	2012	2013				TOTAL
Vaccine stock on 1 January 2011		#		0					
Number of doses per vial		#	1	1	1				
AD syringes required	Select YES or NO	#	Yes	Yes	Yes				
Reconstitution syringes required	Select YES or NO	#	No	No	No				
Safety boxes required	Select YES or NO	#	Yes	Yes	Yes				
Vaccine price per dose	Table 6.1	\$	2.580	2.470	2.320				
Country co-financing per dose		\$	0.30	0.88	1.45				
AD syringe price per unit	Table 6.1	\$	0.053	0.053	0.053				
Reconstitution syringe price per unit	Table 6.1	\$	0.032	0.032	0.032				
Safety box price per unit	Table 6.1	\$	0.640	0.640	0.640				
Freight cost as % of vaccines value	Table 6.2	%	15.00%	15.00%	15.00%				
Freight cost as % of devices value	Table 6.2	%	10.00%	10.00%	10.00%				

Co-financing tables for DTP-HepB-Hib, 1 dose/vial, Liquid

Co-financing group	Graduating
--------------------	------------

	2011	2012	2013		
Minimum co-financing	0.30	0.61	0.92	1.23	1.54
Your co-financing	0.30	0.88	1.45		

Table 7.1.2: Estimated GAVI support and country co-financing (GAVI support)

Supply that is procured by GAVI and related cost in US\$			For Approval	For Endorsement			
Required supply item		2011	2012	2013			TOTAL
Number of vaccine doses	#		47,900	30,400			78,300
Number of AD syringes	#		32,000	21,900			53,900
Number of re-constitution syringes	#		0	0			0
Number of safety boxes	#		375	250			625

Supply that is procured by GAVI and related cost in US\$			For Approval	For Endorsement			
Required supply item		2011	2012	2013			TOTAL
Total value to be co-financed by GAVI	\$		138,500	82,500			221,000

Table 7.1.3: Estimated GAVI support and country co-financing (Country support)

Supply that is procured by the country and related cost in US\$			For approval	For endorsement			
Required supply item		2011	2012	2013			TOTAL
Number of vaccine doses	#		21,100	34,800			55,900
Number of AD syringes	#		14,100	25,100			39,200
Number of re-constitution syringes	#		0	0			0
Number of safety boxes	#		175	300			475
Total value to be co-financed by the country	\$		61,000	94,500			155,500

Table 7.1.4: Calculation of requirements for DTP-HepB-Hib, 1 dose/vial, Liquid

		Formula	2011	2012			2013								
				Total	Gov.	GA VI	Total	Gov.	GA VI	Total	Gov.	GA VI	Total	Gov.	GAVI
A	Country Co-finance			30.51%			53.39%								
B	Number of children to be vaccinated with the first dose	Table 1	13,456	13,692	4,178	9,514	14,073	7,515	6,558						
C	Number of doses per child	Vaccine parameter (schedule)	3	3	3	3	3	3	3						

		Formula	2011	2012			2013								
				Total	Gov.	GA VI	Total	Gov.	GA VI	Total	Gov.	GA VI	Total	Gov.	GAVI
D	Number of doses needed	B x C	40,368	41,076	12,532	28,544	42,219	22,543	19,676						
E	Estimated vaccine wastage factor	Wastage factor table	1.67	1.67	1.67	1.67	1.54	1.54	1.54						
F	Number of doses needed including wastage	D x E	67,415	68,597	20,927	47,670	65,018	34,716	30,302						
G	Vaccines buffer stock	(F – F of previous year) * 0.25		296	91	205	0	0	0						
H	Stock on 1 January 2011			0	0	0									
I	Total vaccine doses needed	F + G - H		68,893	21,018	47,875	65,018	34,716	30,302						
J	Number of doses per vial	Vaccine parameter		1	1	1	1	1	1						
K	Number of AD syringes (+ 10% wastage) needed	(D + G –H) x 1.11		45,923	14,010	31,913	46,864	25,023	21,841						
L	Reconstitution syringes (+ 10% wastage) needed	I / J * 1.11		0	0	0	0	0	0						
M	Total of safety boxes (+ 10% of extra need) needed	(K + L) /100 * 1.11		510	156	354	521	279	242						
N	Cost of vaccines needed	I x g		170,166	51,913	118,253	150,842	80,541	70,301						
O	Cost of AD	K x ca		2,434	743	1,69	2,484	1,327	1,15						

		Formula	2011	2012			2013								
				Total	Gov.	GA VI	Total	Gov.	GA VI	Total	Gov.	GA VI	Total	Gov.	GAVI
	syringes needed					1			7						
P	Cost of reconstitution syringes needed	L x cr		0	0	0	0	0	0						
Q	Cost of safety boxes needed	M x CS		327	100	227	334	179	155						
R	Freight cost for vaccines needed	N x fv		25,525	7,787	17,738	22,627	12,082	10,545						
S	Freight cost for devices needed	(O+P+Q) x fd		277	85	192	282	151	131						
T	Total fund needed	(N+O+P+Q+R+S)		198,729	60,626	138,103	176,569	94,277	82,292						
U	Total country co-financing	I 3 cc		60,626			94,277								
V	Country co-financing % of GAVI supported proportion	U / T		30.51%			53.39%								

8. Injection Safety Support (INS)

There is no INS support this year.

9. Health System Strengthening Programme (HSS)

The HSS form is available at this address: [HSS section of the APR 2010 @ 18 Feb 2011.docx](#)

Please download it, fill it in offline and upload it back at the end of this current APR form using the Attachment section.

10. Civil Society Programme (CSO)

There is no CSO support this year.

11. Comments

Comments from ICC/HSCC Chairs

Please provide any comments that you may wish to bring to the attention of the monitoring IRC in the course of this review and any information you may wish to share in relation to challenges you have experienced during the year under review. These could be in addition to the approved minutes, which should be included in the attachments

Bhutan has requested for penta only for 2012 through APR. We do not need DTP-Hep B in 2012. Please consider penta wastage rate as per the approved rate (1.05) for Bhutan. The request for next tranche for HSS,2012 is USD 40800 consistent with the activities reflected in the cMYP

12. Annexes

Annex 1

TERMS OF REFERENCE:

FINANCIAL STATEMENTS FOR IMMUNISATION SERVICES SUPPORT (ISS) AND NEW VACCINE INTRODUCTION GRANTS

- I. All countries that have received ISS /new vaccine introduction grants during the 2010 calendar year, or had balances of funding remaining from previously disbursed ISS/new vaccine introduction grants in 2010, are required to submit financial statements for these programmes as part of their Annual Progress Reports.
- II. Financial statements should be compiled based upon countries' own national standards for accounting, thus GAVI will not provide a single template to countries with pre-determined cost categories.
- III. **At a minimum**, GAVI requires a simple statement of income and expenditure for activity during the 2010 calendar year, to be comprised of points (a) through (f), below. A sample basic statement of income and expenditure is provided on the next page.
 - a. Funds carried forward from the 2009 calendar year (opening balance as of 1 January 2010)
 - b. Income received from GAVI during 2010
 - c. Other income received during 2010 (interest, fees, etc)
 - d. Total expenditure during the calendar year
 - e. Closing balance as of 31 December 2010
 - f. A detailed analysis of expenditures during 2010, based on **your government's own system of economic classification**. This analysis should summarise total annual expenditure for the year by your government's own system of economic classification, and relevant cost categories, for example: wages & salaries. If possible, please report on the budget for each category at the beginning of the calendar year, actual expenditure during the calendar year, and the balance remaining for each cost category as of 31 December 2010 (referred to as the "variance").
- IV. Financial statements should be compiled in local currency, with an indication of the USD exchange rate applied. Countries should provide additional explanation of how and why a particular rate of exchange has been applied, and any supplementary notes that may help the GAVI Alliance in its review of the financial statements.
- V. Financial statements need not have been audited/certified prior to their submission to GAVI. However, it is understood that these statements should be subjected to scrutiny during each country's external audit for the 2010 financial year. Audits for ISS are due to the GAVI Secretariat 6 months following the close of each country's financial year.

MINIMUM REQUIREMENTS FOR ISS AND VACCINE INTRODUCTION GRANT FINANCIAL STATEMENTS

An example statement of income & expenditure

Summary of income and expenditure – GAVI ISS		
	Local currency (CFA)	Value in USD *
Balance brought forward from 2008 (balance as of 31Decembre 2008)	25,392,830	53,000
Summary of income received during 2009		
Income received from GAVI	57 493 200	120,000
Income from interest	7,665,760	16,000
Other income (fees)	179,666	375
Total Income	38,987,576	81,375
Total expenditure during 2009	30,592,132	63,852
Balance as of 31 December 2009 (balance carried forward to 2010)	60,139,325	125,523

* An average rate of CFA 479,11 = UD 1 applied.

Detailed analysis of expenditure by economic classification ** – GAVI ISS						
	Budget in CFA	Budget in USD	Actual in CFA	Actual in USD	Variance in CFA	Variance in USD
Salary expenditure						
Wedges & salaries	2,000,000	4,174	0	0	2,000,000	4,174
Per diem payments	9,000,000	18,785	6,150,000	12,836	2,850,000	5,949
Non-salary expenditure						
Training	13,000,000	27,134	12 650,000	26,403	350,000	731
Fuel	3,000,000	6,262	4 000,000	8,349	-1,000,000	-2,087
Maintenance & overheads	2,500,000	5,218	1 000,000	2,087	1,500,000	3,131
Other expenditures						
Vehicles	12,500,000	26,090	6,792,132	14,177	5,707,868	11,913
TOTALS FOR 2009	42,000,000	87,663	30,592,132	63,852	11,407,868	23,811

** Expenditure categories are indicative and only included for demonstration purpose. Each implementing government should provide statements in accordance with its own system for economic classification.

TERMS OF REFERENCE: FINANCIAL STATEMENTS FOR HEALTH SYSTEMS STRENGTHENING (HSS)

- I. All countries that have received HSS grants during the 2010 calendar year, or had balances of funding remaining from previously disbursed HSS grants in 2010, are required to submit financial statements for these programmes as part of their Annual Progress Reports.
- II. Financial statements should be compiled based upon countries' own national standards for accounting, thus GAVI will not provide a single template to countries with pre-determined cost categories.
- III. At a minimum, GAVI requires a simple statement of income and expenditure for activity during the 2010 calendar year, to be comprised of points (a) through (f), below. A sample basic statement of income and expenditure is provided on next page.
 - a. Funds carried forward from the 2009 calendar year (opening balance as of 1 January 2010)
 - b. Income received from GAVI during 2010
 - c. Other income received during 2010 (interest, fees, etc)
 - d. Total expenditure during the calendar year
 - e. Closing balance as of 31 December 2010
 - f. A detailed analysis of expenditures during 2010, based on your government's own system of economic classification. This analysis should summarise total annual expenditure for each HSS objective and activity, per your government's originally approved HSS proposal, with further breakdown by cost category (for example: wages & salaries). Cost categories used should be based upon your government's own system for economic classification. Please report the budget for each objective, activity and cost category at the beginning of the calendar year, the actual expenditure during the calendar year, and the balance remaining for each objective, activity and cost category as of 31 December 2010 (referred to as the "variance").
- IV. Financial statements should be compiled in local currency, with an indication of the USD exchange rate applied. Countries should provide additional explanation of how and why a particular rate of exchange has been applied, and any supplementary notes that may help the GAVI Alliance in its review of the financial statements.
- V. Financial statements need not have been audited/certified prior to their submission to GAVI. However, it is understood that these statements should be subjected to scrutiny during each country's external audit for the 2010 financial year. Audits for HSS are due to the GAVI Secretariat 6 months following the close of each country's financial year.

MINIMUM REQUIREMENTS FOR HSS FINANCIAL STATEMENTS:

An example statement of income & expenditure

Summary of income and expenditure – GAVI HSS		
	Local currency (CFA)	Value in USD *
Balance brought forward from 2008 (balance as of 31Decembre 2008)	25,392,830	53,000
Summary of income received during 2009		
Income received from GAVI	57 493 200	120,000
Income from interest	7,665,760	16,000
Other income (fees)	179,666	375
Total Income	38,987,576	81,375
Total expenditure during 2009	30,592,132	63,852
Balance as of 31 December 2009 (balance carried forward to 2010)	60,139,325	125,523

* An average rate of CFA 479,11 = UD 1 applied.

Detailed analysis of expenditure by economic classification ** – GAVI HSS						
	Budget in CFA	Budget in USD	Actual in CFA	Actual in USD	Variance in CFA	Variance in USD
Salary expenditure						
Wedges & salaries	2,000,000	4,174	0	0	2,000,000	4,174
Per diem payments	9,000,000	18,785	6,150,000	12,836	2,850,000	5,949
Non-salary expenditure						
Training	13,000,000	27,134	12 650,000	26,403	350,000	731
Fuel	3,000,000	6,262	4 000,000	8,349	-1,000,000	-2,087
Maintenance & overheads	2,500,000	5,218	1 000,000	2,087	1,500,000	3,131
Other expenditures						
Vehicles	12,500,000	26,090	6,792,132	14,177	5,707,868	11,913
TOTALS FOR 2009	42,000,000	87,663	30,592,132	63,852	11,407,868	23,811

** Expenditure categories are indicative and only included for demonstration purpose. Each implementing government should provide statements in accordance with its own system for economic classification.

Annex 3

TERMS OF REFERENCE: FINANCIAL STATEMENTS FOR CIVIL SOCIETY ORGANISATION (CSO) TYPE B

- I. All countries that have received CSO 'Type B' grants during the 2010 calendar year, or had balances of funding remaining from previously disbursed CSO 'Type B' grants in 2010, are required to submit financial statements for these programmes as part of their Annual Progress Reports.
- II. Financial statements should be compiled based upon countries' own national standards for accounting, thus GAVI will not provide a single template to countries with pre-determined cost categories.
- III. At a minimum, GAVI requires a simple statement of income and expenditure for activity during the 2010 calendar year, to be comprised of points (a) through (f), below. A sample basic statement of income and expenditure is provided on page 3 of this annex.
 - a. Funds carried forward from the 2009 calendar year (opening balance as of 1 January 2010)
 - b. Income received from GAVI during 2010
 - c. Other income received during 2010 (interest, fees, etc)
 - d. Total expenditure during the calendar year
 - e. Closing balance as of 31 December 2010
 - f. A detailed analysis of expenditures during 2010, based on your government's own system of economic classification. This analysis should summarise total annual expenditure by each civil society partner, per your government's originally approved CSO 'Type B' proposal, with further breakdown by cost category (for example: wages & salaries). Cost categories used should be based upon your government's own system for economic classification. Please report the budget for each objective, activity and cost category at the beginning of the calendar year, the actual expenditure during the calendar year, and the balance remaining for each objective, activity and cost category as of 31 December 2010 (referred to as the "variance").
- IV. Financial statements should be compiled in local currency, with an indication of the USD exchange rate applied. Countries should provide additional explanation of how and why a particular rate of exchange has been applied, and any supplementary notes that may help the GAVI Alliance in its review of the financial statements.
- V. Financial statements need not have been audited/certified prior to their submission to GAVI. However, it is understood that these statements should be subjected to scrutiny during each country's external audit for the 2010 financial year. Audits for CSO 'Type B' are due to the GAVI Secretariat 6 months following the close of each country's financial year.

MINIMUM REQUIREMENTS FOR CSO 'Type B' FINANCIAL STATEMENTS

An example statement of income & expenditure

Summary of income and expenditure – GAVI CSO		
	Local currency (CFA)	Value in USD *
Balance brought forward from 2008 (balance as of 31Decembre 2008)	25,392,830	53,000
Summary of income received during 2009		
Income received from GAVI	57 493 200	120,000
Income from interest	7,665,760	16,000
Other income (fees)	179,666	375
Total Income	38,987,576	81,375
Total expenditure during 2009	30,592,132	63,852
Balance as of 31 December 2009 (balance carried forward to 2010)	60,139,325	125,523

* An average rate of CFA 479,11 = UD 1 applied.

Detailed analysis of expenditure by economic classification ** – GAVI CSO						
	Budget in CFA	Budget in USD	Actual in CFA	Actual in USD	Variance in CFA	Variance in USD
Salary expenditure						
Wedges & salaries	2,000,000	4,174	0	0	2,000,000	4,174
Per diem payments	9,000,000	18,785	6,150,000	12,836	2,850,000	5,949
Non-salary expenditure						
Training	13,000,000	27,134	12 650,000	26,403	350,000	731
Fuel	3,000,000	6,262	4 000,000	8,349	-1,000,000	-2,087
Maintenance & overheads	2,500,000	5,218	1 000,000	2,087	1,500,000	3,131
Other expenditures						
Vehicles	12,500,000	26,090	6,792,132	14,177	5,707,868	11,913
TOTALS FOR 2009	42,000,000	87,663	30,592,132	63,852	11,407,868	23,811

** Expenditure categories are indicative and only included for demonstration purpose. Each implementing government should provide statements in accordance with its own system for economic classification.

13. Attachments

13.1. List of Supporting Documents Attached to this APR

Document	Section	Document Number	Mandatory *
Signature of Minister of Health (or delegated authority)		1, 6, 22	Yes
Signature of Minister of Finance (or delegated authority)		14	Yes
Signatures of members of ICC		19	Yes
Signatures of members of HSCC		2	Yes
Minutes of ICC meetings in 2010		3, 4, 20	Yes
Minutes of ICC meeting in 2011 endorsing APR 2010		15	Yes
Minutes of HSCC meetings in 2010		10, 11, 12	Yes
Minutes of HSCC meeting in 2011 endorsing APR 2010		16	Yes
Financial Statement for ISS grant in 2010			
Financial Statement for CSO Type B grant in 2010			
Financial Statement for HSS grant in 2010		8	Yes
EVSM/VMA/EVM report			
External Audit Report (Fiscal Year 2010) for ISS grant			
CSO Mapping Report (Type A)			
New Banking Details			
new cMYP starting 2012			
Summary on fund utilisation of CSO Type A in 2010			
Financial Statement for NVS introduction grant in 2010			
External Audit Report (Fiscal Year 2010) for CSO Type B grant			
External Audit Report (Fiscal Year 2010) for HSS grant			
Latest Health Sector Review Report		9	

13.2. Attachments

List of all the mandatory and optional documents attached to this form

Note: Use the **Upload file** arrow icon to upload the document. Use the **Delete item** icon to delete a line. To add new lines click on the **New item** icon in the **Action** column.

ID	File type	File name	New file	Actions
	Description	Date and Time Size		
1	File Type: Signature of Minister of Health (or delegated authority) *	File name: C:\Documents and Settings\SangayPhuntsho\Desktop\Meeting minutes for GAVI\05-MAY-2004\011908.jpg Date/Time: 13.05.2011 07:18:03 Size: 215 KB		
2	File Type: Signatures of members of HSCC *	File name: C:\Documents and Settings\SangayPhuntsho\Desktop\Meeting minutes for GAVI\05-MAY-2004\012019.jpg Date/Time:		

ID	File type	File name	New file	Actions
	Description	Date and Time Size		
		13.05.2011 07:25:13 Size: 292 KB		
3	File Type: Minutes of ICC meetings in 2010 *	File name: C:\Documents and Settings\SangayPhuntsho\Desktop\Meeting minutes for GAVI\Minutes of 15th PCM[1].doc Date/Time: 13.05.2011 07:32:06 Size: 262 KB		
4	File Type: Minutes of ICC meetings in 2010 *	File name: C:\Documents and Settings\SangayPhuntsho\Desktop\Meeting minutes for GAVI\Minutes Pentavalent Vaccine.docx Date/Time: 13.05.2011 07:38:46 Size: 17 KB		
5	File Type: other File Desc: Cover sheet	File name: C:\Documents and Settings\SangayPhuntsho\Desktop\Meeting minutes for GAVI\05-MAY-2004\012235.jpg Date/Time: 13.05.2011 07:46:18 Size: 144 KB		
6	File Type: Signature of Minister of Health (or delegated authority) *	File name: C:\Documents and Settings\SangayPhuntsho\Desktop\Meeting minutes for GAVI\05-MAY-2004\011908.jpg Date/Time: 13.05.2011 07:53:27 Size: 215 KB		
7	File Type: other File Desc: Cover sheet	File name: C:\Documents and Settings\SangayPhuntsho\Desktop\Meeting minutes for GAVI\05-MAY-2004\012235.jpg Date/Time: 13.05.2011 08:01:44 Size: 144 KB		
8	File Type: Financial Statement for HSS grant in 2010 *	File name: Financial statement2010.pdf Date/Time: 13.05.2011 08:48:09 Size: 1 MB		
9	File Type: Latest Health Sector Review Report File Desc:	File name: BhtJointSectrRevw2009Rept.pdf Date/Time: 13.05.2011 08:55:04 Size: 820 KB		
10	File Type: Minutes of HSCC meetings in 2010 *	File name: PCM1_Minutes.pdf Date/Time: 13.05.2011 09:11:50 Size: 1 MB		
11	File Type: Minutes of HSCC	File name: PCM2_Minutes.pdf		

ID	File type	File name	New file	Actions
	Description	Date and Time Size		
	<u>meetings in 2010 *</u> File Desc:	Date/Time: 13.05.2011 09:22:58 Size: 135 KB		
12	File Type: Minutes of HSCC <u>meetings in 2010 *</u> File Desc:	File name: PCM3_Minutes.pdf Date/Time: 13.05.2011 09:28:16 Size: 108 KB		
13	File Type: other File Desc: APR HSS Section	File name: HSS section of the APR 2010 @ 18 Feb 2011.docx Date/Time: 13.05.2011 09:33:35 Size: 69 KB		
14	File Type: Signature of Minister of Finance (or delegated authority) * File Desc:	File name: Signaturejpg Date/Time: 13.05.2011 09:59:06 Size: 215 KB		
15	File Type: Minutes of ICC meeting in 2011 endorsing APR 2010 * File Desc:	File name: endorsed.jpg Date/Time: 13.05.2011 11:29:46 Size: 292 KB		
16	File Type: Minutes of HSCC meeting in 2011 endorsing APR 2010 * File Desc:	File name: endorsed.jpg Date/Time: 13.05.2011 11:32:09 Size: 292 KB		
17	File Type: other File Desc: Information re penta stock	File name: FW penta stocks.htm Date/Time: 16.06.2011 09:00:34 Size: 28 KB		
18	File Type: other File Desc: Secretariat correspondence with Bhutan	File name: IRC 2011-01-attachments.zip Date/Time: 16.06.2011 09:21:13 Size: 947 KB		
19	File Type: Signatures of members of ICC * File Desc: ICC signature page	File name: Bhutan - ICC signature page.jpg Date/Time: 20.06.2011 06:22:44 Size: 286 KB		
20	File Type: Minutes of ICC meetings in 2010 * File Desc: ICC minutes	File name: Bhutan - Minutes of the meeting_28May2010.docx Date/Time: 20.06.2011 06:23:49 Size: 14 KB		
21	File Type: other File Desc: Note for the record on	File name: Note for Record from the meeting held during Ranjana.docx Date/Time: 22.06.2011 04:17:15		

ID	File type	File name	New file	Actions
	Description	Date and Time Size		
	HSS during GAVI's visit to Bhutan	Size: 12 KB		
22	File Type: Signature of Minister of Health (or delegated authority) * File Desc: HSS documents - September re-submission	File name: Bhutan.zip Date/Time: 05.09.2011 07:45:43 Size: 6 MB		